Dawn Foster
Internal Medicine · Southfield, MINPI 1750449708
Payments from drug & device makers
Across 112 payments — averaging $41.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$839
- AbbVie$493
- GSK$470
- Teva Pharmaceuticals USA, Inc.$364
- Abbott$310
- Novartis$245
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,612100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $839 |
| AbbVie(2 entities) | 18 | $493 |
| GSK | 18 | $470 |
| Teva Pharmaceuticals USA, Inc. | 5 | $364 |
| Abbott | 3 | $310 |
| Novartis | 9 | $245 |
| Novo Nordisk | 9 | $244 |
| Amgen | 3 | $160 |
| Boston Scientific | 2 | $159 |
| Amarin Pharma, Inc. | 1 | $145 |
| Sanofi Pasteur Inc. | 3 | $137 |
| Bayer | 1 | $136 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Modernatx, Inc. | 1 | $121 |
| Abiomed | 2 | $113 |
| Alnylam Pharmaceuticals Inc. | 1 | $111 |
| Johnson & Johnson | 1 | $95 |
| Exact Sciences | 3 | $65 |
| Pfizer | 3 | $52 |
| Boehringer Ingelheim | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Gilead | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| BD | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,612 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $23,044 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $20,861 |
| JanuviaSitagliptin Phosphate | 21 | $20,715 |
| Incruse ElliptaUmeclidinium Bromide | 43 | $17,218 |
| LinzessLinaclotide | 11 | $17,210 |
| MounjaroTirzepatide | 12 | $15,130 |
| TrulicityDulaglutide | 12 | $12,134 |
| JardianceEmpagliflozin | 17 | $11,853 |
| FarxigaDapagliflozin Propanediol | 15 | $8,994 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $6,256 |
| Ventolin HfaAlbuterol Sulfate | 56 | $4,378 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,862 |
| Fluticasone Propionate | 85 | $1,630 |
| Lidocaine | 12 | $1,624 |
| Cyclobenzaprine Hcl | 15 | $1,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $470 | $63,985115 claims |
| Lilly USA, LLCMounjaro, Trulicity | $14 | $27,26424 claims |
| AbbVieLinzess | $493 | $17,21011 claims |
| Boehringer IngelheimJardiance | $30 | $11,85317 claims |
| AstraZenecaFarxiga | $839 | $8,99415 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $364 | $91218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Southfield
- Adam FormanSouthfield$524K
- Talal KhaderSouthfield$319K
- Gregory BergerSouthfield$273K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.